Janux TherapeuticsJANX
JANX
About: Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
Employees: 81
0
Funds holding %
of 7,407 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
267% more first-time investments, than exits
New positions opened: 77 | Existing positions closed: 21
233% more funds holding in top 10
Funds holding in top 10: 3 [Q3] → 10 (+7) [Q4]
91% more call options, than puts
Call options by funds: $37.7M | Put options by funds: $19.7M
88% more repeat investments, than reductions
Existing positions increased: 79 | Existing positions reduced: 42
66% more capital invested
Capital invested by funds: $2.07B [Q3] → $3.43B (+$1.36B) [Q4]
34% more funds holding
Funds holding: 159 [Q3] → 213 (+54) [Q4]
23.5% more ownership
Funds ownership: 87.45% [Q3] → 110.95% (+23.5%) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$41
38%
upside
Avg. target
$56
87%
upside
High target
$70
136%
upside
2 analyst ratings
1 positive
50%
1 neutral
50%
0 negative
0%
HC Wainwright & Co. Swayampakula Ramakanth 23% 1-year accuracy 44 / 192 met price target | 136%upside $70 | Buy Reiterated | 3 Mar 2025 |
Scotiabank George Farmer 19% 1-year accuracy 4 / 21 met price target | 38%upside $41 | Sector Perform Maintained | 28 Feb 2025 |
Financial journalist opinion
Positive
Seeking Alpha
2 weeks ago
Janux Therapeutics: Buying For The Promising Pipeline, Holding For The Buyout
Janux Therapeutics' lead program, JANX007, shows promising early results in prostate cancer, with significant PSA declines and no serious side effects reported. The company's strong financial position, with $1.03 billion in cash, reduces near-term dilution risk and supports pipeline advancement without immediate capital needs. The recent stock pullback presents a buying opportunity, driven by profit-taking and broader market weakness, not negative company updates.
Neutral
24/7 Wall Street
1 month ago
Insiders Are Loading Up on These 4 Biotech Stocks Now
Things are heating up in the biotechnology space, with a flurry of recent initial public offerings and some notable insider purchases of the past week or so.
Neutral
Business Wire
1 month ago
Janux Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a business update. “2024 was an exceptional year for Janux as we displayed t.
Neutral
Business Wire
2 months ago
Janux Therapeutics Promotes Zachariah McIver, D.O., Ph.D. to Chief Medical Officer
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Promotes Zachariah McIver, D.O., Ph.D. to Chief Medical Officer.
Positive
Seeking Alpha
3 months ago
Janux Therapeutics: mCRPC TAM And Promising JANX007's Phase 1 Data
Janux Therapeutics' leading candidate, JANX007, shows high efficacy and safety in Phase 1 trials for metastatic castration-resistant prostate cancer, targeting a multi-billion dollar TAM. Janux's TRACTr and TRACIr platforms differentiate it in immunotherapy by enabling tumor-activated bispecific therapeutics for precise cancer targeting with minimal systemic toxicity. JANX's robust balance sheet, with $658.1 million in liquid assets and no debt. Oppenheimer identified Janux as a top biotech buyout candidate for 2025, citing its innovative platform and promising.
Positive
Seeking Alpha
3 months ago
Best-Performing Stocks Of 2024
Taking a look at the 20 best-performing stocks in 2024 of current Russell 3,000 members.
Neutral
Business Wire
4 months ago
Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the closing of its previously announced underwritten public offering of 6,150,793 shares of its common stock, which includes the exercise in full by the underwriters of.
Neutral
Business Wire
4 months ago
Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the pricing of an underwritten public offering of 5,317,460 shares of its common stock at a public offering price of $63.00 per share and pre-funded warrants to purchas.
Positive
The Motley Fool
4 months ago
Why Janux Therapeutics Crushed the Market Today
News of an analyst's price-target hike plus a new round of capital-raising were the sparks that ignited Janux Therapeutics (JANX 11.65%) stock on Wednesday. The clinical-stage biotech's share price ended the day nearly 12% higher, and this was on a very good day for the exchange with the S&P 500 rising by 0.6%.
Positive
Zacks Investment Research
4 months ago
JANX Stock Hits Record High on Prostate Cancer Study Data
An early-stage study data shows that treatment with Janux's JANX007 generates deep and durable efficacy responses in heavily pretreated patients with mCRPC.
Charts implemented using Lightweight Charts™